Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of
Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain
Officers.
On April 6, 2017, Joseph Del Guercio informed Nuo Therapeutics,
Inc. (the Company) that he was resigning from the board of
directors of the Company (the Board), effective upon the
appointment of his successor. Effective as of April 7, 2017, the
Companys Board appointed Paul D. Mintz, MD to fill the vacancy
created by Mr. Del Guercios resignation. The Board also appointed
Dr. Mintz to its Compensation Committee and its Nominating and
Corporate Governance Committee. Dr. Mintz will be compensated
consistent with the compensation program applicable to
non-management members of the Board.
On April 10, 2017, the Company issued a press release announcing
this change in the membership of the Companys Board, which is
attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
|
(d) Exhibits Exhibit Number |
Description |
|
99.1 |
Press Release of Nuo Therapeutics, Inc., dated April 10, 2017 |
About Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ)
Nuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc. Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) Recent Trading Information
Nuo Therapeutics, Inc. (OTCMKTS:NUOTQ) closed its last trading session at 0.0120 with 51,009 shares trading hands.
